GLP-1s: A Quiet Drop-Off in Seniors

For many seniors, breakthrough weight-loss drugs deliver real benefits — until insurance denials, side effects, or muscle loss force them to quit.

1

Older adults represent a significant demographic for GLP-1 medications, with obesity prevalence around 40% and Type 2 diabetes nearly 30% in those 65 and older.
2

Approximately 60% of seniors with diabetes discontinue semaglutide within a year, with older patients 20% to 30% more likely to stop using GLP-1s.
3

Common side effects of GLP-1s include gastrointestinal issues, which may lead to discontinuation, impacting weight loss and overall health.
4

Financial barriers significantly affect GLP-1 usage, with many patients citing cost or insurance coverage as reasons for discontinuation.
5

Potential changes in Medicare regulations may expand coverage for GLP-1s for weight loss, addressing an important gap in treatment for obesity in seniors.

1